<DOC>
	<DOC>NCT00403559</DOC>
	<brief_summary>This is an exploratory study to determine effectiveness of Elidel for the treatment of seborrheic dermatitis</brief_summary>
	<brief_title>A 4 Week Study of Elidel for the Treatment of Seborrheic Dermatitis</brief_title>
	<detailed_description>This is a 4 week study for patients 18 and olderto compare the efficacy and safety of pimecrolimus cream 1% twice daily and ketaconazole cream 2 % twice daily for the treatment of seborrheic dermatitis.</detailed_description>
	<mesh_term>Dermatitis</mesh_term>
	<mesh_term>Dermatitis, Seborrheic</mesh_term>
	<mesh_term>Pimecrolimus</mesh_term>
	<criteria>Must be 18 or older and sign written informed consent. Must be wiling and able to comply with protocol. Must have active seborrheic dermatitis of the face. No history of overt bacterial, viral or fungal infection of the head/neck. No history or presence of compromising dermatosis elsewhere on the skin No Parkinson's disease, HIV, infections or disorders of the central nervous system No actinically damaged skin</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2007</verification_date>
	<keyword>seborrheic dermatitis</keyword>
</DOC>